| The Australian Pharmaceutical Benefits Scheme data collection: a practical guide for researchers L Mellish, EA Karanges, MJ Litchfield, AL Schaffer, B Blanch, BJ Daniels, ... BMC research notes 8, 1-13, 2015 | 315 | 2015 |
| Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011 CP Stephenson, E Karanges, IS McGregor Australian & New Zealand Journal of Psychiatry 47 (1), 74-87, 2013 | 308 | 2013 |
| Cannabidiol potentiates Δ9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats C Klein, E Karanges, A Spiro, A Wong, J Spencer, T Huynh, ... Psychopharmacology 218, 443-457, 2011 | 241 | 2011 |
| Twenty‐five years of prescription opioid use in Australia: a whole‐of‐population analysis using pharmaceutical claims EA Karanges, B Blanch, NA Buckley, SA Pearson British journal of clinical pharmacology 82 (1), 255-267, 2016 | 199 | 2016 |
| Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey EA Karanges, A Suraev, N Elias, R Manocha, IS McGregor BMJ open 8 (7), e022101, 2018 | 152 | 2018 |
| Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009–2012: Focus on children, adolescents and prescriber specialty EA Karanges, CP Stephenson, IS McGregor Australian & New Zealand Journal of Psychiatry 48 (10), 917-931, 2014 | 124 | 2014 |
| Psychotropic medication use in Australia, 2007 to 2015: changes in annual incidence, prevalence and treatment exposure J Brett, EA Karanges, B Daniels, NA Buckley, C Schneider, A Nassir, ... Australian & New Zealand Journal of Psychiatry 51 (10), 990-999, 2017 | 84 | 2017 |
| Trends in self-poisoning and psychotropic drug use in people aged 5–19 years: a population-based retrospective cohort study in Australia R Cairns, EA Karanges, A Wong, JA Brown, J Robinson, SA Pearson, ... BMJ open 9 (2), e026001, 2019 | 75 | 2019 |
| Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion CP Motbey, E Karanges, KM Li, S Wilkinson, AR Winstock, J Ramsay, ... Public Library of Science 7 (9), e45473, 2012 | 67 | 2012 |
| To what extent do data from pharmaceutical claims under‐estimate opioid analgesic utilisation in Australia? N Gisev, SA Pearson, EA Karanges, B Larance, NA Buckley, S Larney, ... Pharmacoepidemiology and drug safety 27 (5), 550-555, 2018 | 49 | 2018 |
| Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents? E Karanges, KM Li, C Motbey, PD Callaghan, A Katsifis, IS McGregor International Journal of Neuropsychopharmacology 14 (4), 491-504, 2011 | 49 | 2011 |
| Trends in opioid utilisation in Australia, 2006‐2015: insights from multiple metrics EA Karanges, NA Buckley, J Brett, B Blanch, M Litchfield, L Degenhardt, ... Pharmacoepidemiology and drug safety 27 (5), 504-512, 2018 | 47 | 2018 |
| Psychotropic polypharmacy in Australia, 2006 to 2015: a descriptive cohort study J Brett, B Daniels, EA Karanges, NA Buckley, C Schneider, A Nassir, ... British journal of clinical pharmacology 83 (11), 2581-2588, 2017 | 44 | 2017 |
| Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: an observational study L Parker, EA Karanges, L Bero BMJ open 9 (2), e024928, 2019 | 33 | 2019 |
| Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of “paradoxical” antidepressant … EA Karanges, MA Kashem, R Sarker, EU Ahmed, S Ahmed, ... Frontiers in pharmacology 4, 86, 2013 | 29 | 2013 |
| Antidepressants and adolescent brain development E Karanges, IS McGregor Future Neurology 6 (6), 783-808, 2011 | 26 | 2011 |
| The changing face of Australian data reforms: impact on pharmacoepidemiology research J de Oliveira Costa, C Bruno, AL Schaffer, S Raichand, EA Karanges, ... International Journal of Population Data Science 6 (1), 2021 | 18 | 2021 |
| Pharmaceutical industry payments to leaders of professional medical associations in Australia:'Focus on cardiovascular disease and diabetes' EA Karanges, N Ting, L Parker, A Fabbri, L Bero Australian Journal of General Practice 49 (3), 151-154, 2020 | 16 | 2020 |
| Understanding the nature and extent of pharmaceutical industry payments to nonphysician clinicians EA Karanges, Q Grundy, L Bero JAMA Internal Medicine 179 (10), 1430-1432, 2019 | 14 | 2019 |
| Pharmaceutical industry funding of events for healthcare professionals on non-vitamin K oral anticoagulants in Australia: an observational study B Behdarvand, EA Karanges, L Bero BMJ open 9 (8), e030253, 2019 | 14 | 2019 |
